Autoimmune Connective Tissue Diseases

  • Julia S. LehmanEmail author
  • Alina G. Bridges


Autoimmune connective tissue diseases (CTD) include a variety of chronic autoimmune disorders that may affect one or multiple organ systems, with the skin being frequently involved. Accurate diagnosis of this category of diseases is critically dependent on careful correlation amongst clinical features, laboratory studies, histopathologic findings, and clinical course, with no single feature being pathognomonic. Often, patients are best served by a multidisciplinary care team, with representatives from rheumatology, dermatology, and other subspecialists as directed by each patient’s pattern of disease. Generally, affected patients require ongoing follow-up for monitoring of disease activity and treatment response, as well as surveillance for evolution of their disease. This chapter will provide a general overview of key systemic features of each major CTD, with particular emphasis to the dermatologic and dermatopathologic manifestations.


Autoimmune connective tissue diseases Lupus erythematosus Dermatomyositis Rheumatoid arthritis Systemic sclerosis Interface dermatitis 


  1. 1.
    Hile GA, Gudjonsson JE, Kahlenberg JM. The influence of interferon on healthy and diseased skin. Cytokine. 2018. ePub ahead of print.Google Scholar
  2. 2.
    Hoffmann JH, Enk AH. Neutrophil extracellular traps in dermatology: caught in the NET. J Dermatol Sci. 2016;84(1):3–10.PubMedCrossRefGoogle Scholar
  3. 3.
    Sarkar MK, Hile GA, Tsoi LC, Xing X, Liu J, Liang Y, et al. Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa. Ann Rheum Dis. 2018;77(11):1653–64.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Szczech J, Samotij D, Werth VP, Reich A. Trigger factors of cutaneous lupus erythematosus: a review of current literature. Lupus. 2017;26(8):791–807.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Contestable JJ, Edhegard KD, Meyerle JH. Bullous systemic lupus erythematosus: a review and update to diagnosis and treatment. Am J Clin Dermatol. 2014;15(6):517–24.PubMedCrossRefGoogle Scholar
  6. 6.
    Ribero S, Sciascia S, Borradori L, Lipsker D. The cutaneous spectrum of lupus erythematosus. Clin Rev Allergy Immunol. 2017;53(3):291–305.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–86.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Tedeschi SK, Johnson SR, Boumpas DT, Daikh D, Dorner T, Diamond B, et al. Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(5):634–40.Google Scholar
  9. 9.
    Stannard JN, Kahlenberg JM. Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus. Curr Opin Rheumatol. 2016;28(5):453–9.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Antiga E, Caproni M, Bonciani D, Bonciolini V, Fabbri P. The last word on the so-called ‘Rowell’s syndrome’? Lupus. 2012;21(6):577–85.PubMedCrossRefGoogle Scholar
  11. 11.
    Gonzalez-Cruz C, Aparicio Espanol G, Ferrer Fabrega B, Cabezas Calderon V, Giner Pichel M, Garcia-Patos BV. Lupus panniculitis: Clinicopathological features of a series of 12 patients. Medicina clinica. 2018;151(11):444–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Cappel JA, Wetter DA. Clinical characteristics, etiologic associations, laboratory findings, treatment, and proposal of diagnostic criteria of pernio (chilblains) in a series of 104 patients at Mayo Clinic, 2000 to 2011. Mayo Clin Proc. 2014;89(2):207–15.PubMedCrossRefGoogle Scholar
  13. 13.
    Vanoni F, Lava SAG, Fossali EF, Cavalli R, Simonetti GD, Bianchetti MG, et al. Neonatal systemic lupus erythematosus syndrome: a comprehensive review. Clin Rev Allergy Immunol. 2017;53(3):469–76.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Concha JSS, Werth VP. Alopecias in lupus erythematosus. Lupus Sci Med. 2018;5(1):e000291.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Brinster NK, Nunley J, Pariser R, Horvath B. Nonbullous neutrophilic lupus erythematosus: a newly recognized variant of cutaneous lupus erythematosus. J Am Acad Dermatol. 2012;66(1):92–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Wang MZ, Camilleri MJ, Guo R, Wieland CN. Amicrobial pustulosis of the folds: report of 4 cases. J Cutan Pathol. 2017;44(4):367–72.PubMedCrossRefGoogle Scholar
  17. 17.
    Lee WJ, Kang HJ, Shin HJ, Won CH, Chang SE, Choi JH, et al. Neutrophilic urticarial dermatosis and sweet-like neutrophilic dermatosis: under-recognized neutrophilic dermatoses in lupus erythematosus. Lupus. 2018;27(4):628–36.PubMedCrossRefGoogle Scholar
  18. 18.
    Sopena B, Rivera A, Chamorro A, Freire M, Alende V, Seco E, et al. Clinical association between Kikuchis disease and systemic lupus erythematosus: a systematic literature review. Semin Arthritis Rheum. 2017;47(1):46–52.PubMedCrossRefGoogle Scholar
  19. 19.
    Vaglio A, Grayson PC, Fenaroli P, Gianfreda D, Boccaletti V, Ghiggeri GM, et al. Drug-induced lupus: traditional and new concepts. Autoimmun Rev. 2018;17(9):912–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Lowe GC, Henderson CL, Grau RH, Hansen CB, Sontheimer RD. A systematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol. 2011;164(3):465–72.PubMedGoogle Scholar
  21. 21.
    Wieczorek IT, Propert KJ, Okawa J, Werth VP. Systemic symptoms in the progression of cutaneous to systemic lupus erythematosus. JAMA Dermatol. 2014;150(3):291–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Davis MD, Daoud MS, Kirby B, Gibson LE, Rogers RS 3rd. Clinicopathologic correlation of hypocomplementemic and normocomplementemic urticarial vasculitis. J Am Acad Dermatol. 1998;38(6 Pt 1):899–905.PubMedGoogle Scholar
  23. 23.
    Wang ML, Chan MP. Comparative analysis of chilblain lupus erythematosus and idiopathic perniosis: histopathologic features and immunohistochemistry for CD123 and CD30. Am J Dermatopathol. 2018;40(4):265–71.PubMedCrossRefGoogle Scholar
  24. 24.
    de Risi-Pugliese T, Cohen Aubart F, Haroche J, Moguelet P, Grootenboer-Mignot S, Mathian A, et al. Clinical, histological, immunological presentations and outcomes of bullous systemic lupus erythematosus: 10 new cases and a literature review of 118 cases. Semin Arthritis Rheum. 2018;48(1):83–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Ko CJ, Srivastava B, Braverman I, Antaya RJ, McNiff JM. Hypertrophic lupus erythematosus: the diagnostic utility of CD123 staining. J Cutan Pathol. 2011;38(11):889–92.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Chen SJT, Tse JY, Harms PW, Hristov AC, Chan MP. Utility of CD123 immunohistochemistry in differentiating lupus erythematosus from cutaneous T-cell lymphoma. Histopathology. 2019;74(6):908–16.Google Scholar
  27. 27.
    Sharon VR, Konia TH, Barr KL, Fung MA. Assessment of the ‘no eosinophils’ rule: are eosinophils truly absent in pityriasis lichenoides, connective tissue disease, and graft-vs.-host disease? J Cutan Pathol. 2012;39(4):413–8.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Cardinali C, Caproni M, Fabbri P. The composition of the lupus band test (LBT) on the sun-protected non-lesional (SPNL) skin in patients with cutaneous lupus erythematosus (CLE). Lupus. 1999;8(9):755–60.PubMedCrossRefGoogle Scholar
  29. 29.
    Fung MA, Sharon VR, Ratnarathorn M, Konia TH, Barr KL, Mirmirani P. Elastin staining patterns in primary cicatricial alopecia. J Am Acad Dermatol. 2013;69(5):776–82.PubMedCrossRefGoogle Scholar
  30. 30.
    George SM, Taylor MR, Farrant PB. Psoriatic alopecia. Clin Exp Dermatol. 2015;40(7):717–21.PubMedCrossRefGoogle Scholar
  31. 31.
    LeBlanc RE, Tavallaee M, Kim YH, Kim J. Useful parameters for distinguishing subcutaneous panniculitis-like T-cell lymphoma from lupus erythematosus panniculitis. Am J Surg Pathol. 2016;40(6):745–54.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Verdelli A, Antiga E, Bonciolini V, Bonciani D, Volpi W, Caproni M. Drug induction in connective tissue diseases. G Ital Dermatol Venereol. 2014;149(5):573–80.PubMedGoogle Scholar
  33. 33.
    Seidler AM, Gottlieb AB. Dermatomyositis induced by drug therapy: a review of case reports. J Am Acad Dermatol. 2008;59(5):872–80.PubMedCrossRefGoogle Scholar
  34. 34.
    Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Bailey EE, Fiorentino DF. Amyopathic dermatomyositis: definitions, diagnosis, and management. Curr Rheumatol Rep. 2014;16(12):465.PubMedCrossRefGoogle Scholar
  36. 36.
    Bendewald MJ, Wetter DA, Li X, Davis MD. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County. Minnesota Arch Dermatol. 2010;146(1):26–30.PubMedGoogle Scholar
  37. 37.
    Sontheimer RD. Cutaneous features of classic dermatomyositis and amyopathic dermatomyositis. Curr Opin Rheumatol. 1999;11(6):475–82.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Mainetti C, Terziroli Beretta-Piccoli B, Selmi C. Cutaneous manifestations of dermatomyositis: a comprehensive review. Clin Rev Allergy Immunol. 2017;53(3):337–56.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Daly ML, Gordon PA, Creamer D. Cutaneous features of dermatomyositis associated with myositis-specific antibodies. Br J Dermatol. 2017;176(6):1662–5.PubMedCrossRefGoogle Scholar
  40. 40.
    Di Rollo D, Abeni D, Tracanna M, Capo A, Amerio P. Cancer risk in dermatomyositis: a systematic review of the literature. G Ital Dermatol Venereol. 2014;149(5):525–37.PubMedGoogle Scholar
  41. 41.
    Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011;65(1):25–34.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Magro CM, Crowson AN. The immunofluorescent profile of dermatomyositis: a comparative study with lupus erythematosus. J Cutan Pathol. 1997;24(9):543–52.PubMedCrossRefGoogle Scholar
  43. 43.
    Ferreli C, Gasparini G, Parodi A, Cozzani E, Rongioletti F, Atzori L. Cutaneous manifestations of scleroderma and scleroderma-like disorders: a comprehensive review. Clin Rev Allergy Immunol. 2017;53(3):306–36.PubMedCrossRefGoogle Scholar
  44. 44.
    Fett N, Werth VP. Update on morphea: part I. epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2011;64(2):217–28. quiz 29-30PubMedCrossRefGoogle Scholar
  45. 45.
    Fruchter R, Kurtzman DJB, Mazori DR, Wright NA, Patel M, Vleugels RA, et al. Characteristics and treatment of postirradiation morphea: a retrospective multicenter analysis. J Am Acad Dermatol. 2017;76(1):19–21.PubMedCrossRefGoogle Scholar
  46. 46.
    Trattner A, David M, Sandbank M. Bullous morphea: a distinct entity? Am J Dermatopathol. 1994;16(4):414–7.PubMedCrossRefGoogle Scholar
  47. 47.
    Khelifa E, Masouye I, Pham HC, Parmentier L, Borradori L. Linear sclerodermic lupus erythematosus, a distinct variant of linear morphea and chronic cutaneous lupus erythematous. Int J Dermatol. 2011;50(12):1491–5.PubMedCrossRefGoogle Scholar
  48. 48.
    Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23(5):581–590.Google Scholar
  49. 49.
    Shah AA, Wigley FM, Hummers LK. Telangiectases in scleroderma: a potential clinical marker of pulmonary arterial hypertension. J Rheumatol. 2010;37(1):98–104.PubMedCrossRefGoogle Scholar
  50. 50.
    Leitenberger JJ, Cayce RL, Haley RW, Adams-Huet B, Bergstresser PR, Jacobe HT. Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol. 2009;145(5):545–50.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Yang S, Draznin M, Fung MA. The “line sign” is a rapid and efficient diagnostic “test” for morphea: clinicopathological study of 73 cases. Am J Dermatopathol. 2018;40(12):873–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Perez-Chua TA, Kisel YG, Chang KH, Bhawan J. Morphea and its variants and the “floating sign”-an additional finding in morphea. Am J Dermatopathol. 2014;36(6):500–5.PubMedCrossRefGoogle Scholar
  53. 53.
    Onajin O, Wieland CN, Peters MS, Lohse CM, Lehman JS. Clinicopathologic and immunophenotypic features of eosinophilic fasciitis and morphea profunda: a comparative study of 27 cases. J Am Acad Dermatol. 2018;78(1):121–8.PubMedCrossRefGoogle Scholar
  54. 54.
    Generali E, Costanzo A, Mainetti C, Selmi C. Cutaneous and mucosal manifestations of Sjogren’s syndrome. Clin Rev Allergy Immunol. 2017;53(3):357–70.PubMedCrossRefGoogle Scholar
  55. 55.
    Haridas V, Shetty P, Dsouza LC, Dinesh US, Haridas K, Bargale A. Pyoderma gangrenosum in Sjogren’s syndrome and its successful treatment with topical application of etanercept. Int J Rheum Dis. 2017;20(5):657–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Schulze-Koops H, Kalden JR. The balance of Th1/Th2 cytokines in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2001;15(5):677–91.PubMedCrossRefGoogle Scholar
  57. 57.
    Lora V, Cerroni L, Cota C. Skin manifestations of rheumatoid arthritis. G Ital Dermatol Venereol. 2018;153(2):243–55.PubMedGoogle Scholar
  58. 58.
    Tilstra JS, Lienesch DW. Rheumatoid Nodules. Dermatol Clin. 2015;33(3):361–71.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Requena L, El-Shabrawi-Caelen L, Walsh SN, Segura S, Ziemer M, Hurt MA, et al. Intralymphatic histiocytosis. A clinicopathologic study of 16 cases. Am J Dermatopathol. 2009;31(2):140–51.PubMedCrossRefGoogle Scholar
  60. 60.
    Lynch JM, Barrett TL. Collagenolytic (necrobiotic) granulomas: part II--the ‘red’ granulomas. J Cutan Pathol. 2004;31(6):409–18.PubMedCrossRefGoogle Scholar
  61. 61.
    Kumar B, Singh N, Rahnama-Moghadam S, Wanat KA, Ijdo JW, Werth VP. Multicentric reticulohistiocytosis: a multicenter case series and review of literature. J Clin Rheumatol: Pract Rep Rheumatic Musculoskeletal Dis. 2018;24(1):45–9.CrossRefGoogle Scholar
  62. 62.
    Jurado SA, Alvin GK, Selim MA, Pipkin CA, Kress D, Jamora MJ, et al. Fibroblastic rheumatism: a report of 4 cases with potential therapeutic implications. J Am Acad Dermatol. 2012;66(6):959–65.PubMedCrossRefGoogle Scholar
  63. 63.
    Foidart JM, Abe S, Martin GR, Zizic TM, Barnett EV, Lawley TJ, et al. Antibodies to type II collagen in relapsing polychondritis. N Engl J Med. 1978;299(22):1203–7.PubMedCrossRefGoogle Scholar
  64. 64.
    Orme RL, Nordlund JJ, Barich L, Brown T. The MAGIC syndrome (mouth and genital ulcers with inflamed cartilage). Arch Dermatol. 1990;126(7):940–4.PubMedCrossRefGoogle Scholar
  65. 65.
    Shimizu J, Yamano Y, Kawahata K, Suzuki N. Relapsing polychondritis patients were divided into three subgroups: patients with respiratory involvement (R subgroup), patients with auricular involvement (A subgroup), and overlapping patients with both involvements (O subgroup), and each group had distinctive clinical characteristics. Medicine (Baltimore). 2018;97(42):e12837.CrossRefGoogle Scholar
  66. 66.
    Schreiber BE, Twigg S, Marais J, Keat AC. Saddle-nose deformities in the rheumatology clinic. Ear Nose Throat J. 2014;93(4–5):E45–7.PubMedGoogle Scholar
  67. 67.
    Moreira A, Torres B, Peruzzo J, Mota A, Eyerich K, Ring J. Skin symptoms as diagnostic clue for autoinflammatory diseases. An Bras Dermatol. 2017;92(1):72–80.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Sun NZ, Brezinski EA, Berliner J, Haemel A, Connolly MK, Gensler L, et al. Updates in adult-onset still disease: atypical cutaneous manifestations and associations with delayed malignancy. J Am Acad Dermatol. 2015;73(2):294–303.PubMedCrossRefGoogle Scholar
  69. 69.
    Broekaert SM, Boer-Auer A, Kerl K, Herrgott I, Schulz X, Bonsmann G, et al. Neutrophilic epitheliotropism is a histopathological clue to neutrophilic urticarial dermatosis. Am J Dermatopathol. 2016;38(1):39–49.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Departments of Dermatology and Laboratory Medicine and PathologyMayo ClinicRochesterUSA

Personalised recommendations